– USA, CA – Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced the appointment of Gregory Lucier as Chairperson of the Board of Directors, effective May 14, 2021, succeeding Michael Marks, who is retiring from the Board.
Concurrent with this appointment, John Chiminski, CEO and chairperson of Catalent, will join the Board as an independent director.
About Greg Lucier
Mr. Lucier is CEO of Corza Health, which in partnership with private equity firm GTCR, provides governance, strategic insights, and growth capital to expand the equity value of companies across the life sciences and MedTech industries. Before Corza Health, he most recently served as CEO at NuVasive. Before that, he was CEO at Life Technologies—formerly Invitrogen—which he grew into a global life sciences powerhouse that was acquired by Thermo Fisher Scientific for approximately $15 billion. Mr. Lucier serves on several public and private company boards, including Catalent, Dentsply Sirona, and Maravai Life Sciences.
“I am honored to be appointed Board Chair and continue to work alongside the Berkeley Lights team to enable a future where cells are a scalable and sustainable way to manufacture the products that we need to live a long and healthy life,” said Greg Lucier. “The Berkeley Lights Platform is key to enabling this future by providing precise, rapid discovery and functional validation of biology.”
He holds a Bachelor’s in Industrial Engineering from Pennsylvania State University and a Master’s in Business Administration from Harvard Business School.
About John Chiminski
Mr. Chiminski has been the CEO of Catalent, Inc. since 2009 and also serves as the Board chairperson. Before Catalent, he spent more than 20 years with GE Healthcare, including serving as president and CEO of GE Medical Diagnostics, a global business with sales of $1.9 billion. From 2005 to 2007, Mr. Chiminski served as vice president and general manager of GE Healthcare’s Global Magnetic Resonance Business, and from 2001 to 2005, as vice president and general manager of Global Healthcare Services. Earlier in his career, he held a series of cross-functional leadership positions in both manufacturing and engineering. In 2019, Mr. Chiminski was selected as the inaugural recipient of the CPhl Pharma Lifetime Achievement Award.
“I am excited to join Berkeley Lights and be part of an organization that is transforming the cell-based product value chain across a wide range of applications and markets,” said Mr. Chiminski. “The Berkeley Lights platform is incredibly powerful, and I look forward to helping guide the Company into its next phase of growth.”
He holds a B.S. from Michigan State University and an M.S. from Purdue University, both in electrical engineering, as well as a Master’s Degree in Management from the Kellogg School of Management at Northwestern University.
About Berkeley Lights
Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.
For more information: https://www.berkeleylights.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.